Cargando…

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

BACKGROUND/AIMS: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 204...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Michael H., Yeo, Yee Hui, Zou, Biyao, Barnet, Scott, Henry, Linda, Cheung, Ramsey, Nguyen, Mindie H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597215/
https://www.ncbi.nlm.nih.gov/pubmed/36117442
http://dx.doi.org/10.3350/cmh.2022.0239
_version_ 1784816043556864000
author Le, Michael H.
Yeo, Yee Hui
Zou, Biyao
Barnet, Scott
Henry, Linda
Cheung, Ramsey
Nguyen, Mindie H.
author_facet Le, Michael H.
Yeo, Yee Hui
Zou, Biyao
Barnet, Scott
Henry, Linda
Cheung, Ramsey
Nguyen, Mindie H.
author_sort Le, Michael H.
collection PubMed
description BACKGROUND/AIMS: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040. METHODS: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality. RESULTS: The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85). CONCLUSION: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease.
format Online
Article
Text
id pubmed-9597215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-95972152022-10-31 Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Le, Michael H. Yeo, Yee Hui Zou, Biyao Barnet, Scott Henry, Linda Cheung, Ramsey Nguyen, Mindie H. Clin Mol Hepatol Original Article BACKGROUND/AIMS: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040. METHODS: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality. RESULTS: The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85). CONCLUSION: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease. The Korean Association for the Study of the Liver 2022-10 2022-09-19 /pmc/articles/PMC9597215/ /pubmed/36117442 http://dx.doi.org/10.3350/cmh.2022.0239 Text en Copyright © 2022 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Le, Michael H.
Yeo, Yee Hui
Zou, Biyao
Barnet, Scott
Henry, Linda
Cheung, Ramsey
Nguyen, Mindie H.
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
title Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
title_full Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
title_fullStr Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
title_full_unstemmed Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
title_short Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
title_sort forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597215/
https://www.ncbi.nlm.nih.gov/pubmed/36117442
http://dx.doi.org/10.3350/cmh.2022.0239
work_keys_str_mv AT lemichaelh forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach
AT yeoyeehui forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach
AT zoubiyao forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach
AT barnetscott forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach
AT henrylinda forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach
AT cheungramsey forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach
AT nguyenmindieh forecasted2040globalprevalenceofnonalcoholicfattyliverdiseaseusinghierarchicalbayesianapproach